PDF(Pubmed)
Abstract：
UNASSIGNED: While oral acetazolamide is a cornerstone of management of adult and pediatric PTCS, previous studies have suggested that acetazolamide used in children with other conditions may influence growth.
UNASSIGNED: Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available before and during acetazolamide treatment (n=22).
UNASSIGNED: Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.
UNASSIGNED: Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.
UNASSIGNED: Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available before and during acetazolamide treatment (n=22).
UNASSIGNED: Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.
UNASSIGNED: Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.
摘要：
■虽然口服乙酰唑胺是治疗成人和儿童PTCS的基石，先前的研究表明，乙酰唑胺用于其他疾病的儿童可能会影响生长。
■涉及单个三级医疗中心的回顾性图表审查。确定了34名患有明确或可能的PTCS的儿童。分析仅限于在乙酰唑胺治疗之前和期间可获得人体测量数据的个体（n=22）。
■一半的个体（n=11/22）显示BMIZ得分下降。63％（n=14/22）在使用乙酰唑胺治疗期间显示身高Z评分降低；在这14名具有完整数据的儿童中，有6名，图3显示在停止乙酰唑胺后高度Z-评分的至少部分恢复。
■乙酰唑胺可能与某些接受儿童PTCS治疗的儿童的生长抑制有关。在某些情况下,一旦停止乙酰唑胺，生长抑制似乎逆转。
■涉及单个三级医疗中心的回顾性图表审查。确定了34名患有明确或可能的PTCS的儿童。分析仅限于在乙酰唑胺治疗之前和期间可获得人体测量数据的个体（n=22）。
■一半的个体（n=11/22）显示BMIZ得分下降。63％（n=14/22）在使用乙酰唑胺治疗期间显示身高Z评分降低；在这14名具有完整数据的儿童中，有6名，图3显示在停止乙酰唑胺后高度Z-评分的至少部分恢复。
■乙酰唑胺可能与某些接受儿童PTCS治疗的儿童的生长抑制有关。在某些情况下,一旦停止乙酰唑胺，生长抑制似乎逆转。
